Modern aspects of angina treatment in arterial hypertension patients: emphasizing endothelial function role
Abstract
This literature review is analyzing heart rate (HR) role in the pathogenesis of arterial hypertension (AH) and coronary heart disease (CHD), together with HR prognostic role in assessing cardiovascular event risk. Modern approaches to pharmaceutical CHD treatment in Stage I-II AH patients, are analyzed from the evidence-based medicine point of view. Antianginal and antihypertensive agents' effects on endothelial function and microcirculation in this clinical group are discussed. The recent information on HR-decelerating medications' effects on stable angina clinical course and prognosis is presented. The authors justify the need for further investigation of ivabradine role in combined pharmaceutical treatment of cardiovascular disease.
About the Authors
L. L. Kirichenko
Moscow State MedicoStomatological University. Moscow
Russian Federation
Russian Federation
A. N. Golosova
Moscow State MedicoStomatological University. Moscow
Russian Federation
Russian Federation
S. V. Gatsura
Moscow State MedicoStomatological University. Moscow
Russian Federation
Russian Federation
A. P. Korolev
Moscow State MedicoStomatological University. Moscow
Russian Federation
Russian Federation
P. P. Struchkov
Moscow State MedicoStomatological University. Moscow
Russian Federation
Russian Federation
Zh. D. Dvoryanchikova
Moscow State MedicoStomatological University. Moscow
Russian Federation
Russian Federation
References
1. Карпов Ю.А., Буза В.В. Ивабрадин как новая составляющая эффективного лечения больных стабильной стенокардией. Сердце 2006; 5: 248-52.
2. Kannel W., Feinleib M. Natural hystory of angina pectoris in the Framingham Study. Prognosis and survival. Am J Cardiol 1972; 29(2):154-63.
3. Маколкин В.И., Зябрев Ф.Н. Почему надо снижать частоту сердечных сокращений при лечении стабильной стенокардии? Кардиология 2006; 9: 88-91.
4. Sigh B.N. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Cardiovasc Pharmacol Ther 2001; 6: 313-31.
5. Шальнова C.A., Деев А.Д., Оганов Р.Г. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. // Кардиология. 2005. № 10. С. 45.
6. Wilhelmsen L., Berlund G., Elmfeldt D., et al. The multifactor primary prevention trial in Geteborg, Sweden. Eur Heart J 1986; 7: 279-88.
7. Карпов Ю.А., Шальнова С.А., Деев АД. от имени участников программы. Исследование ПРЕМЬЕРА: достижение целевого уровня артериального давления -успех в лечении ишемической болезни сердца. Кардиоваск тер профил 2006; 6: 53-60.
8. Dawber T.R. The Framingham study. The epidemiology of atherosclerotic disease. Cambridge: Harvard University Press 1980.
9. Nitenberg A., Antony I. Epicardial coronary arteries are not adequatly sized in hypertensive patients. JACC 1996; 27: 115-23.
10. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
11. Российские рекомендации по диагностике и лечению стабильной стенокардии. Сердце 2006; 2: 86-100.
12. Dalen J.E. Aspirin to prevent heart attack and Stroke: what's the right dose? Am J Med 2006; 119(3): 198-202.
13. Карпов Ю.А., Шубина A.T. Бета-блокаторы в лечении и профилактике ишемической болезни сердца. Сердце 2005; 1:32-5.
14. Beta-blocker Heart Attack Trial Research Group (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247: 1707-14.
15. The HOPE Study Investigators. Effects of an angitensine-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-53.
16. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
17. Task Force Members, Lopez-Sendon J, Swedberg K, et al. Expert consensus document on beta-blockers of the European Society of Cardiology. Eur Heart J 2004; 25: 1341-62.
18. Карпов Ю.А. Ингибиторы ангиотензинпревращающего фермента у больных ишемической болезнью сердца: при высоком риске осложнений или всем? Кардиология 2005; 9: 4-10.
19. Лопатин Ю.М. Антигипертензивные эффекты ингибитора ангиотензинпревращающего фермента периндоприла (взгляд с позиции исследования ASCOT-BPLA). Кардиоваск тер профил 2006; 3: 83-7.
20. Mancini G.B.J., Henry G.C., Macaya C. et al. Angiotensin-converting engime inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND Study. Circulation 1996; 94: 258-65.
21. Ющук E.H., Васюк Ю.А., Хадзегоева А.Б. и др. Эндотелиальная дисфункция при заболеваниях сердечно-сосудистой системы и методы ее коррекции. Клин фармак тер 2005;4: 85-90.
22. Sowers J.R. Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002; 346: 1999-2001.
23. Kiowski W., Linder L., Nuesch R. Effects of angiotensin converting enzyme inhibition on endothelial vasodilatator function in primary human hypertension. Eur Heart J 1993; 14: 5-9.
24. Мареев В.Ю. Путь к исследованию EUROPA: успехи и неудачи. Серд недостат 2004; 2: 80-1.
25. Ferrari R. EUROPA: perindopril's action on markers of thrombosis, inflammation, and endothelial dysfunction in coroi artery disease. Oral presentation. A Satellite Symposium during the ESC Congress Munich 2004.
26. Ferrari R. PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction. Oral presentation. Notline session I held during the ESC Congress. Stochkgolm 2005.
27. Chillon J.C., Baumbach G.L. Effects of an angiotensin-converting enzyme inhibitor and a b-blocker on cerebral arterioles in rates. Hypertens 1999; 33: 856-61.
28. Rizzoni D., Castellano M., Porteti E. et al. Vascular structural and functional alterations before and after the development of hypertension in SHR. J Hypertens 1994; 7: 193-200.
29. Thybo N.K., Stephens N., Cooper A. et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential Hypertension. Hypertension 1995; 25: 474-81.
30. Scheidegger K.J., Wood J.V., Van Essen H. et al. Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneosly hypertensive rats. J Pharmacol Exp Ther 1996; 278: 1276-81.
31. Bock P. The arterial length-densities under preventive angiotensin-converting-enzyme inhibiting treatment in the myocardium of spotaneneosly hypertensive rats. Basic Res Cardiol 1998; 93: 18-22.
32. Levy B.I., Duriez M., Samuel J.L. Coronary microvasculature alteration in hypertensive rats: effect of treatment with a diuretic and an ACE inhibitor. Am J Hypertens 2001; 14: 7-13.
33. Rakusan K., Cicutti N., Maurin A., et al. The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone SHR. Microvasc Res 2000; 59: 243-54.
34. Singh B.N. Morbidity and mortality in cardiovascular disorders: impact of Reduced Heart Rate. J Cardiovasc Pharmacol Ther 2001; 6(4): 313-31.
35. Ferrari R. Editorial: heart rate. Eur Heart J 2003; 5: 1-2.
36. Kannel W., Kannel C., Paffenbarger R. et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-94.
37. Giflum R., Makuc D., Feldman J. Pulse rate, coronary heart disease, and death: The NHANES I epidemiologic follow-up study. Am Heart J 1991; 121: 172-7.
38. Gillman M.W., Kannel W.B., Belanger A.D. Agostino R.B. Influence of heart rate oh mortality among persons with hypertension: the Fremingham Study. Am Heart J 1993; 125: 1148-54.
39. Белоусов Ю.Б., Ерофеева С.Б., Манешина О.А. Ивабрадин -первый If ингибитор избирательного и специфического действия, новый препарат для лечения стабильной стенокардии. Кардиология 2006; 8: 36-48.
40. DiFrancesco D., Camm A. Heart rate lowering by specific and selective If current inhibition with Ivabradin. Drugs 2004; 16(64): 1757-63.
41. Patel S., Breall J., Diver D. et al. Bradycardia is associated with development of coronary collateral vessels in humans. Coron Artery Dis 2000; 11(6): 467-72.
42. Diaz A., Bourassa M.G., Guertin M.C. et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary arteriy disease. Eur Heart J 2005; 26(10): 967-74.
43. Von Arnim T. Medical treatment to reduce total ischemic burden: total iscemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipin. TIBBS Investigators. JACC 1995; 25: 231-8.
44. Plosker G.L., Clissold S.P. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Drugs 1992; 43: 382-414.
45. Tuomilehto J., Wikstrand J., Olsson G., et al. Decreased coronary heart disease in hypertensive smokers. Mortality results from the MARHY study. Hypertension 1989; 13: 773-80.
46. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1327-32.
47. Task Force Members., Lopez-Sendon J., Swedberg K. et al. Expert consensus document on beta-blockers of the European Society of Cardiology. Eur Heart J 2004; 25: 1341-62.
48. Conn P.F., Deedwania P.C. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994; 90(2): 762-8.
49. Smith S.C., Blair S.N., Bonow R.O. et al. AHA ACC Scientific Statement: AHA ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001; 104(13): 1577-9.
50. Guth B.D., Indolfi C., Heusch G. et al. Mechanisms of benefit in the ischemic myocardium due to heart rate reduction. Basic Res Cardiol 1990; 85:157-66.
51. Kop W.J., Verdino R.J., Gottdiener J.S. et al. Changes in heart rate and heart rate variability before ambulatory ischemic events. JACC 2001; 38: 742-9.
52. Hjalmarson A., Gilpin E., Kjekshus J. et al. Influence of heartrate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547-53.
53. Kjekshus J.K. Importance of heart rate in determining β-blocker efficacy in acute and long term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57(12): 43-9.
54. Ко D.T., Hebert P.R., Coffey C.S. et al. β-blocker therapy ahd symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351-7.
55. Lewis R.V., Lofthouse C. Adverse reaction with p-adrenoceptor blocking drugs. An update. Drug Saf 1993; 9(4): 272-9.
56. Кириченко Л.Л., Вострякова О.В., Бабич Ю.А. и др. Состояние микроциркуляции у больных артериальной гипертонией на фоне применения бета-блокаторов. Кардиоваск тер профил 2006; 6: 27-31.
57. Parenti A., Fillipi S., Amerini S. et al. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 2000; 292: 698-703.
58. Подзолков В.И., Булатов В.А. Нарушения микроциркуляции при артериальной гипертензии: причина, следствие или еще один «порочный круг»? Сердце 2005; 3: 132-7.
59. Thollon С., Cambarant С., Vian J. et al. Electrophysiological effect of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparation: comparison with UL-FS49. Br J Pharmacol 1994; 112: 37-42.
60. Vilaine J.P., Bidouard J.P., Lesage L. et al. Anti-ischemic effects of ivabradine, a selective heart rate reducing agent, in exercise induced myocardial ischemia in pigs. J Cardiovasc Pharmacol 2003; 42: 688-96.
61. Monnet X., Ghaleh B., Colin P. et al. Effect of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Ext Ther 2001; 299(3): 1133-9.
62. Simon L., Ghelen B., Puybasset L. et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Ext Ther 1995; 275: 659-66.
63. Vilaine J.P., Thollon C., Villeneuve N. et al. Procoranal, a new selective If current inhibitor. Eur Heart J 2003; 5: 26-35.
64. Borer J.S., Fox K., Jaillon P., et al. Antianginal and antiischemic effects of ivabradine, an 1 (f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107(6): 821-3.
65. Weber M.A., Smith D.H., Neutel J.M., Graettinger W.F. Cardiovascular and metabolic characteristics of hypertension. Am J Med 1991; 91: 4-10.
66. Ruzyllo W., Ford I., Tendera M. et al. Antianginal and anti-ischemic effects of the If current inhibitor ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina: A 3-month randomized, controlled, double-blind, multi-center trial. Eur Heart J 2004; 25(Abstract): 878.
67. Tardif J.C., Ford I., Tendera M. et al. On behalf of INITIATIVE study group. Antianginal and anti-ischemic effects of the If current inhibitor ivabradine compared to atenolol as monotherapies with chronic stable angina. A 3-month randomized, controlled, double-blind, multi-center trial. Eur Heart J 2003; 25(Abstracts): 186.
68. Lopez-Bescos L. Long-term safety and antianginal efficacy of the If current inhibitor ivabradine in patients with chronic stable angina. Eur Heart J 2004; 25(Abstract): 876.
69. Tardif J.C., Berry С. From coronary artery disease to heart failure: potential benefits of ivabradine. Eur Heart J 2006; 8(Suppl. D): 24-9.
70. Fox K. Contribution of perindopril to cardiology: 20 years of success. Eur Heart J 2006; 9(Suppl. E): 10-9.
71. ACC/AHA/ACP-ACIM Guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Task Force
72. PROGRESS Collaborative group. Effect of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475-84.
Review
For citations:
Kirichenko L.L., Golosova A.N., Gatsura S.V., Korolev A.P., Struchkov P.P., Dvoryanchikova Zh.D. Modern aspects of angina treatment in arterial hypertension patients: emphasizing endothelial function role. Cardiovascular Therapy and Prevention. 2008;7(2):109-116. (In Russ.)
Views:
432
Email this article 
